Core Viewpoint - Juzi Biotechnology (02367) experienced a rebound of over 8%, with a current price of HKD 41.9 and a trading volume of HKD 400 million [1] Group 1: Shareholder Activity - Juzi Holding, the controlling shareholder, purchased 500,000 shares of the company on the announcement date, amounting to approximately HKD 19.3 million [1] - Since the disclosure of the buyback plan on June 9, 2025, Juzi Holding has cumulatively acquired 3.666 million shares, investing a total of about HKD 178 million [1] - Following these purchases, Juzi Holding's shareholding increased to 585 million shares, representing 54.61% of the company's total issued shares, with intentions to further increase holdings based on market conditions and regulatory requirements [1] Group 2: Market Analysis - Citigroup recently released a report indicating that the market's reaction to Juzi Biotechnology's pre-sale performance decline during the Double 11 event, particularly in Li Jiaqi's live-streaming sales, is overly pessimistic [1] - Although Li Jiaqi's live-streaming sales are a significant indicator for Double 11 performance, the contribution from other KOLs and the company's own live-streaming efforts has been rapidly increasing, reducing reliance on any single influencer [1] - Despite the competitive landscape, there has been no negative feedback from customers regarding the company's products or brand [1] - Given the low base this year, Citigroup anticipates a recovery in sales for Juzi Biotechnology in the fiscal year 2026, maintaining that the company's valuation remains attractive [1]

Core Viewpoint - Juzi Biotechnology (02367.HK) is experiencing significant stock price volatility due to poor sales performance in live streaming, leading to a decline in market confidence and a substantial drop in stock value [1][2] Group 1: Shareholding and Stock Performance - Juzi Holding, the controlling shareholder, purchased 500,000 shares for approximately HKD 19.3 million, increasing its total holdings to 5.85 billion shares, representing 54.61% of the company's issued shares [1] - The company's stock price recently fell from a high of HKD 87.1 per share on May 20 to a low of HKD 56.2 per share by June 9, resulting in a market value loss exceeding HKD 30 billion [1] - The latest stock price is HKD 38.62, with a market capitalization of HKD 41.36 billion [1] Group 2: Financial Performance - Juzi Biotechnology reported a revenue of HKD 3.113 billion for the first half of 2025, a year-on-year increase of 22.5%, and a net profit of HKD 1.182 billion, up 20.6% [2] - The projected revenue for 2024 is HKD 5.538 billion, reflecting a 57.2% year-on-year growth, with a net profit forecast of HKD 2.061 billion, a 42.4% increase [2] - The company has significantly increased its sales and distribution expenses, with a projected expenditure of HKD 2.008 billion in 2024, up 72.51% from HKD 1.164 billion in 2023 [2] Group 3: Market Position and Challenges - Juzi Biotechnology is a leading player in the restructured collagen market, with its brand Kefu Mei achieving rapid growth and becoming a top domestic brand [2] - The company has faced challenges due to ongoing disputes regarding the authenticity of collagen content, which has affected consumer confidence and market perception [1]

Core Points - Juzi Holding Co., Ltd, the controlling shareholder of the company, has purchased a total of 500,000 shares in the market, amounting to approximately HKD 19.3 million, to support the company's sustainable and healthy development [1] - Since the announcement of the share purchase plan on June 9, 2025, Juzi Holding has acquired a total of 3,666,600 shares, with a total investment of about HKD 178 million [1] - Following this latest purchase, Juzi Holding now holds a total of 584,771,535 shares, representing 54.61% of the company's total issued shares [1] - Juzi Holding may continue to increase its shareholding based on market conditions and applicable regulatory requirements [1]

巨子生物(02367)公布，董事会接获公司控股股东Juzi Holding Co.,Ltd(Juzi Holding)通知，基于对公司未 来发展的强烈信心，为促进公司持续、稳定、健康发展，维护广大公众投资者利益，于本公告日期， Juzi Holding于市场内合共购入50万股公司股份，本次增持金额合计约为1930万港元(不包括佣金及其他 开支)。自2025年6月9日发布增持计划后，截至本公告日期，Juzi Holding于市场内共购入366.66万股公 司股份，增持金额合计约为1.784亿元港币(不包括佣金及其他开支)。紧随本次增持后，于本公告日期， JuziHolding合共持有公司584,771,535股股份，占公司已发行总股数的54.61%。JuziHolding可能会根据市 场状况和适用的监管要求，不时进一步增持公司股份。 ...

本 公 司 股 東 及 有 意 投 資 者 於 買 賣 本 公 司 股 份 時 務 請 審 慎 行 事。 承董事會命 GIANT BIOGENE HOLDING CO., LTD 巨子生物控股有限公司 （於 開 曼 群 島 註 冊 成 立 的 獲 豁 免 有 限 公 司） （股 份 代 號：2367） 自願性公告 控股股東增持股份 本公告乃由巨子生物控股有限公司（「本公司」）自 願 作 出。兹 提 述 本 公 司 日 期 為 2025年6月9日 的 公 告，內 容 有 關 控 股 股 東 增 持 本 公 司 股 份 的 計 劃。 本公司董事會（（「董事會」）接獲本公司控股股東Juzi Holding Co., Ltd（「Juzi Holding」） 通 知，基 於 對 本 公 司 未 來 發 展 的 強 烈 信 心，為 促 進 本 公 司 持 續、穩 定、健 康 發 展，維 護 廣 大 公 眾 投 資 者 利 益，於 本 公 告 日 期，Juzi Holding於市場內合共購入 500,000股本公司股份（「本次增持」），本 次 增 持 金 額 合 計 約 為19.3百萬港元（不 包 括 佣 金 及 其 他 ...

每经AI快讯，巨子生物(02367.HK)再跌超4%，较年内高点85.79港元已腰斩，截至发稿，跌4.01%，报 39.22港元，成交额7.45亿港元。 ...

Core Viewpoint - The stock of Giant Bio (02367) has dropped over 4%, halving from its year-to-date high of 85.79 HKD, currently trading at 39.22 HKD with a transaction volume of 745 million HKD [1] Group 1: Company Performance - The pre-sale performance of Giant Bio's subsidiary, Kefu Mei, during this year's "Double Eleven" event has been lackluster [1] - According to Citigroup's report, the main products of Giant Bio showed a decline in performance during the pre-sale on October 15 in Li Jiaqi's live stream [1] - Citigroup noted that the company's promotional strategy has become more stringent, making its pricing less attractive compared to other brands [1] Group 2: Market Reaction and Future Outlook - Citigroup believes that the market's reaction to the decline in pre-sale performance during the first day of Double Eleven is overblown [1] - Although sales trends from Li Jiaqi's live streaming are important indicators for Double Eleven performance, the contribution from this channel has significantly decreased due to the growth of other KOLs and the company's own live streaming efforts [1] - Despite the intense competition, there has been no negative feedback from customers regarding the company's products or brand [1] - Given the low base this year, Citigroup expects Giant Bio's sales to recover in the fiscal year 2026, and the company's valuation remains attractive [1]

Core Viewpoint - The stock of Giant Bio (02367) has dropped over 4%, halving from its year-to-date high of 85.79 HKD, currently trading at 39.22 HKD with a transaction volume of 745 million HKD [1] Group 1: Company Performance - Giant Bio's subsidiary, Kefu Mei, has shown lackluster performance in pre-sales during this year's "Double Eleven" event [1] - According to Citigroup's report, the main products of Giant Bio experienced a decline in performance during the pre-sale on October 15 in Li Jiaqi's live streaming session [1] - Citigroup noted that the company's promotional strategy has become more stringent, making its pricing less attractive compared to other brands [1] Group 2: Market Reaction and Future Outlook - Citigroup believes that the market's reaction to the decline in pre-sale performance during the Double Eleven event is overly pessimistic [1] - Although Li Jiaqi's live streaming sales trend is an important indicator for Double Eleven performance, the contribution from this channel has significantly decreased due to the growth of other KOLs and the company's own live streaming efforts [1] - Despite the intense competition, there has been no negative feedback from customers regarding the company's products or brand [1] - Given the low base this year, Citigroup expects Giant Bio's sales to recover in the fiscal year 2026, and the company's valuation remains attractive [1]

Core Viewpoint - The stock of Giant Bio (02367) has been transferred from the Shenzhen-Hong Kong Stock Connect to the Shanghai-Hong Kong Stock Connect, with a market value of HKD 887 million, accounting for 2.05% of the total [1] Group 1: Company Performance - Citigroup predicts that Giant Bio's performance in Q3 and the first two weeks of October is relatively weak due to fewer KOL live streams [1] - The expected revenue growth for Giant Bio in the second half of the year is 16% year-on-year, with Tmall projected to decline by 10%, Douyin to increase by 25%, JD.com to grow by 100%, and offline sales to rise by 10% [1] - Citigroup also anticipates that Giant Bio's revenue for the fiscal year 2026 will continue to grow at a high rate of 19% from a low base, as there are no negative feedbacks from customers [1]

Core Viewpoint - The recent stock transfer of Giant Bio (02367) from Hong Kong Stock Connect (Shenzhen) to Hong Kong Stock Connect (Shanghai) indicates a strategic shift, with a market capitalization of HKD 887 million, representing 2.05% of the total [1] Group 1: Company Performance - Citigroup predicts that Giant Bio's performance in Q3 and the first two weeks of October is relatively weak due to fewer KOL live streams [1] - The revenue growth forecast for the second half of the year is 16% year-on-year, with specific expectations of a 10% decline on Tmall, a 25% increase on Douyin, a 100% increase on JD.com, and a 10% growth offline [1] - Citigroup anticipates that Giant Bio's revenue will continue to grow at a high rate of 19% in the fiscal year 2026, supported by a low base and no negative feedback from customers [1]